tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Chemomab Therapeutics Announces Key Decisions from Annual Shareholders Meeting
PremiumCompany AnnouncementsChemomab Therapeutics Announces Key Decisions from Annual Shareholders Meeting
2M ago
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Premium
The Fly
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
2M ago
Chemomab obtained feedback from two recent FDA meetings on nebokitug
Premium
The Fly
Chemomab obtained feedback from two recent FDA meetings on nebokitug
2M ago
Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer
PremiumThe FlyChemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer
3M ago
Chemomab Therapeutics Advances Nebokitug Towards Phase 3 After Positive Trial Results
Premium
Company Announcements
Chemomab Therapeutics Advances Nebokitug Towards Phase 3 After Positive Trial Results
3M ago
Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year
Premium
The Fly
Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year
3M ago
Chemomab Announces Key Leadership Changes Amid Successful Trial Completion
PremiumCompany AnnouncementsChemomab Announces Key Leadership Changes Amid Successful Trial Completion
4M ago
Chemomab Therapeutics appoints Weiner as interim CMO, Lawler as CDO
Premium
The Fly
Chemomab Therapeutics appoints Weiner as interim CMO, Lawler as CDO
4M ago
Promising Phase 3 Prospects and Strategic Study Design Justify Buy Rating for Chemomab Therapeutics
Premium
Ratings
Promising Phase 3 Prospects and Strategic Study Design Justify Buy Rating for Chemomab Therapeutics
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100